Sigma (σ) receptors as potential therapeutic targets to mitigate psychostimulant effects

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 323-386

  Matsumoto, Rae R ^a   Nguyen, Linda ^a   Kaushal, Nidhi ^a,b   Robson, Matthew J ^a,c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Cocaine; Glia; Methamphetamine; Neurotoxicity; Sigma receptor

Indexed keywords

AMFEBUTAMONE; COCAINE; DONEPEZIL; HALOPERIDOL; IGMESINE; METHAMPHETAMINE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIPRAMOL; PANAMESINE; PRASTERONE; PSYCHOSTIMULANT AGENT; RECEPTOR SUBTYPE; SEROTONIN; SERTRALINE; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; CENTRAL STIMULANT AGENT;

ARTICLE; ASTROCYTE; BEHAVIOR; CELL TYPE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); CONDITIONING; CONVULSION; DRUG EFFECT; ENDOTHELIUM CELL; GLIA; HUMAN; HYPERTHERMIA; IMAGING; IN VIVO STUDY; LETHALITY; LEUKOCYTE; LOCOMOTION; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SENSITIZATION; ADDICTION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN BINDING; REVIEW;

ADDICTION; COCAINE; GLIA; METHAMPHETAMINE; NEUROTOXICITY; SIGMA RECEPTOR;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; COCAINE; DRUG DELIVERY SYSTEMS; HUMANS; METHAMPHETAMINE; OPIPRAMOL; PROTEIN BINDING; RECEPTORS, SIGMA; SUBSTANCE-RELATED DISORDERS;

EID: 84893187276     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00009-3     Document Type: Chapter

References (231)

1. Ahmed I.S., Chamberlain C., Craven R.J. S2R(Pgrmc1): The cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opinion on Drug Metabolism & Toxicology 2012, 8(3):361-370. 10.1517/17425255.2012.658367.
2. 1 receptor in the adult rat central nervous system. Neuroscience 2000, 97(1):155-170. S0306452200000142 [pii].
3. Aydar R., Palmer C.P., Djamgoz M.B. Sigma receptors and cancer: Possible involvement of ion channels. Cancer Research 2004, 64(15):5029-5035.
4. Aydar E., Palmer C.P., Klyachko V.A., Jackson M.B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34(3):399-410. S0896627302006773 [pii].
5. Balasuriya D., Stewart A.P., Crottes D., Borgese F., Soriani O., Edwardson J.M. The sigma-1 receptor binds to the Nav1.5 voltage-gated Na+ channel with 4-fold symmetry. The Journal of Biological Chemistry 2012, 287(44):37021-37029. M112.382077 [pii]. 10.1074/jbc.M112.382077.
6. Basile A.S., Paul I.A., de Costa B. Differential effects of cytochrome P-450 induction on ligand binding to sigma receptors. European Journal of Pharmacology 1992, 227(1):95-98.
7. Bastianetto S., Rouquier L., Perrault G., Sanger D.J. DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways. Neuropharmacology 1995, 34(3):281-287. 002839089400156M [pii].
8. Berger S.P., Hall S., Mickalian J.D., Reid M.S., Crawford C.A., Delucchi K., et al. Haloperidol antagonism of cue-elicited cocaine craving. Lancet 1996, 347(9000):504-508.
9. Bermack J.E., Debonnel G. The role of sigma receptors in depression. Journal of Pharmacological Sciences 2005, 97(3):317-336. JST.JSTAGE/jphs/CRJ04005X [pii].
10. 3H](+)pentazocine binding sites in the rat brain: Autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 1997, 76(2):467-477. S0306-4522(96)00221-7 [pii].
11. Bourrie B., Bribes E., De Nys N., Esclangon M., Garcia L., Galiegue S., et al. SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. European Journal of Pharmacology 2002, 456(1-3):123-131.
12. Bourrie B., Bribes E., Derocq J.M., Vidal H., Casellas P. Sigma receptor ligands: Applications in inflammation and oncology. Current Opinion in Investigational Drugs 2004, 5(11):1158-1163.
13. 3H]-(+)-Pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors. Molecular Neuropharmacology 1993, 3:117-126.
14. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics 1994, 268(3):1571-1580.
15. Brackett R.L., Pouw B., Blyden J.F., Nour M., Matsumoto R.R. Prevention of cocaine-induced convulsions and lethality in mice: Effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology 2000, 39(3):407-418. S0028390899001513 [pii].
16. 1 receptors. European Journal of Pharmacology 2006, 553(1-3):141-145. S0014-2999(06)01070-3 [pii]. 10.1016/j.ejphar.2006.09.038.
17. Callaghan R.C., Cunningham J.K., Sykes J., Kish S.J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug and Alcohol Dependence 2012, 120(1-3):35-40. S0376-8716(11)00276-6 [pii]. 10.1016/j.drugalcdep.2011.06.013.
18. 3H](+)-pentazocine binding sites on cells of the immune system. Journal of Neuroimmunology 1991, 35(1-3):153-166.
19. Chen J.C., Chen P.C., Chiang Y.C. Molecular mechanisms of psychostimulant addiction. Chang Gung Medical Journal 2009, 32(2):148-154. 3202/320204 [pii].
20. Cobos E.J., Baeyens J.M., Del Pozo E. Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 2005, 55(3):192-195. 10.1002/syn.20103.
21. Connor M.A., Chavkin C. Focal stimulation of specific pathways in the rat hippocampus causes a reduction in radioligand binding to the haloperidol-sensitive sigma receptor. Experimental Brain Research 1991, 85(3):528-536.
22. Connor M.A., Chavkin C. Ionic zinc may function as a endogenous ligand for the haloperidol-sensitive sigma 2 receptor in rat brain. Molecular Pharmacology 1992, 42(3):471-479.
23. Contreras P.C., DiMaggio D.A., O'Donohue T.L. An endogenous ligand for the sigma opioid binding site. Synapse 1987, 1(1):57-61. 10.1002/syn.890010108.
24. Crawford K.W., Bowen W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Research 2002, 62(1):313-322.
25. Crawford K.W., Coop A., Bowen W.D. sigma2 Receptors regulate changes in sphingolipid levels in breast tumor cells. European Journal of Pharmacology 2002, 443(1-3):207-209. S0014299902015819 [pii].
26. Crottes D., Martial S., Rapetti-Mauss R., Pisani D.F., Loriol C., Pellissier B., et al. Sig1R protein regulates hERG channel expression through a post-translational mechanism in leukemic cells. The Journal of Biological Chemistry 2011, 286(32):27947-27958. M111.226738 [pii]. 10.1074/jbc.M111.226738.
27. Cuevas J., Rodriguez A., Behensky A., Katnik C. Afobazole modulates microglial function via activation of both sigma-1 and sigma-2 receptors. The Journal of Pharmacology and Experimental Therapeutics 2011, 339(1):161-172. jpet.111.182816 [pii]. 10.1124/jpet.111.182816.
28. Derlet R.W., Albertson T.E. Anticonvulsant modification of cocaine-induced toxicity in the rat. Neuropharmacology 1990, 29(3):255-259.
29. Dhir A., Kulkarni S.K. Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor. Fundamental & Clinical Pharmacology 2008, 22(4):387-394. FCP605 [pii]. 10.1111/j.1472-8206.2008.00605.x.
30. ++ influx and beating rate in cultured cardiac myocytes. The Journal of Pharmacology and Experimental Therapeutics 1994, 269(3):1300-1309.
31. Eugenin E.A., Osiecki K., Lopez L., Goldstein H., Calderon T.M., Berman J.W. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: A potential mechanism of HIV-CNS invasion and NeuroAIDS. The Journal of Neuroscience 2006, 26(4):1098-1106. 26/4/1098 [pii]. 10.1523/JNEUROSCI.3863-05.2006.
32. Fiala M., Gan X.H., Zhang L., House S.D., Newton T., Graves M.C., et al. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis?. Advances in Experimental Medicine and Biology 1998, 437:199-205.
33. Fishback J.A., Robson M.J., Xu Y.T., Matsumoto R.R. Sigma receptors: Potential targets for a new class of antidepressant drug. Pharmacology & Therapeutics 2010, 127(3):271-282. S0163-7258(10)00077-X [pii]. 10.1016/j.pharmthera.2010.04.003.
34. Fishback J.A., Rosen A., Bhat R., McCurdy C.R., Matsumoto R.R. A 96-well filtration method for radioligand binding analysis of sigma receptor ligands. Journal of Pharmaceutical and Biomedical Analysis 2012, 71:157-161. S0731-7085(12)00429-3 [pii]. 10.1016/j.jpba.2012.07.023.
35. Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323(5916):934-937. 323/5916/934 [pii]. 10.1126/science.1166127.
36. Frieboes R.M., Murck H., Wiedemann K., Holsboer F., Steiger A. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 1997, 132(1):82-88.
37. Ganapathy M.E., Prasad P.D., Huang W., Seth P., Leibach F.H., Ganapathy V. Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. The Journal of Pharmacology and Experimental Therapeutics 1999, 289(1):251-260.
38. Gebreselassie D., Bowen W.D. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. European Journal of Pharmacology 2004, 493(1-3):19-28. S0014299904003802 [pii]. 10.1016/j.ejphar.2004.04.005.
39. Gekker G., Hu S., Sheng W.S., Rock R.B., Lokensgard J.R., Peterson P.K. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. International Immunopharmacology 2006, 6(6):1029-1033. S1567-5769(05)00354-1 [pii]. 10.1016/j.intimp.2005.12.005.
40. Goldstein S.R., Matsumoto R.R., Thompson T.L., Patrick R.L., Bowen W.D., Walker J.M. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 1989, 4(3):254-258. 10.1002/syn.890040311.
41. Gonzalez R., Bechara A., Martin E.M. Executive functions among individuals with methamphetamine or alcohol as drugs of choice: Preliminary observations. Journal of Clinical and Experimental Neuropsychology 2007, 29(2):155-159. 770388106 [pii]. 10.1080/13803390600582446.
42. Gough B., Imam S.Z., Blough B., Slikker W., Ali S.F. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: A microdialysis study. Annals of the New York Academy of Sciences 2002, 965:410-420.
43. Grasing K., Mathur D., Newton T.F., DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug and Alcohol Dependence 2010, 107(1):69-75. S0376-8716(09)00365-2 [pii]. 10.1016/j.drugalcdep.2009.09.010.
44. Graybiel A.M., Besson M.J., Weber E. Neuroleptic-sensitive binding sites in the nigrostriatal system: Evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat. The Journal of Neuroscience 1989, 9(1):326-338.
45. 2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology 1999, 146(1):81-86. 91460081.213 [pii].
46. 3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. The Journal of Neuroscience 1986, 6(6):1757-1770.
47. Ha Y., Dun Y., Thangaraju M., Duplantier J., Dong Z., Liu K., et al. Sigma receptor 1 modulates endoplasmic reticulum stress in retinal neurons. Investigative Ophthalmology & Visual Science 2011, 52(1):527-540. iovs.10-5731 [pii]. 10.1167/iovs.10-5731.
48. Hall A.A., Herrera Y., Ajmo C.T., Cuevas J., Pennypacker K.R. Sigma receptors suppress multiple aspects of microglial activation. Glia 2009, 57(7):744-754. 10.1002/glia.20802.
49. Han D.D., Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology 2006, 6:6. 1471-2210-6-6 [pii]. 10.1186/1471-2210-6-6.
50. 1-binding site. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(15):8072-8077.
51. Hart C.L., Marvin C.B., Silver R., Smith E.E. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology 2012, 37(3):586-608. npp2011276 [pii]. 10.1038/npp.2011.276.
52. Hayashi T., Justinova Z., Hayashi E., Cormaci G., Mori T., Tsai S.Y., et al. Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. The Journal of Pharmacology and Experimental Therapeutics 2010, 332(3):1054-1063. jpet.109.159244 [pii]. 10.1124/jpet.109.159244.
53. 2+ concentration. The Journal of Pharmacology and Experimental Therapeutics 2000, 293(3):788-798.
54. Hayashi T., Su T.P. Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004, 18(5):269-284.
55. 2+ signaling and cell survival. Cell 2007, 131(3):596-610. S0092-8674(07)01099-9 [pii]. 10.1016/j.cell.2007.08.036.
56. Hayashi T., Tsai S.Y., Mori T., Fujimoto M., Su T.P. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opinion on Therapeutic Targets 2011, 15(5):557-577. 10.1517/14728222.2011.560837.
57. Hebert M.A., O'Callaghan J.P. Protein phosphorylation cascades associated with methamphetamine-induced glial activation. Annals of the New York Academy of Sciences 2000, 914:238-262.
58. Hellewell S.B., Bowen W.D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Research 1990, 527(2):244-253. 0006-8993(90)91143-5 [pii].
59. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., Bowen W.D. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: Characterization by ligand binding and photoaffinity labeling. European Journal of Pharmacology 1994, 268(1):9-18.
60. Hiranita T., Mereu M., Soto P.L., Tanda G., Katz J.L. Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists. Neuropsychopharmacology 2013, 38(4):605-615. npp2012224 [pii]. 10.1038/npp.2012.224.
61. Hiranita T., Soto P.L., Kohut S.J., Kopajtic T., Cao J., Newman A.H., et al. Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and sigma receptors. The Journal of Pharmacology and Experimental Therapeutics 2011, 339(2):662-677. jpet.111.185025 [pii]. 10.1124/jpet.111.185025.
62. Hiranita T., Soto P.L., Tanda G., Katz J.L. Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine. The Journal of Pharmacology and Experimental Therapeutics 2010, 332(2):515-524. jpet.109.159236 [pii]. 10.1124/jpet.109.159236.
63. Hiranita T., Soto P.L., Tanda G., Katz J.L. Lack of cocaine-like discriminative-stimulus effects of sigma-receptor agonists in rats. Behavioural Pharmacology 2011, 22(5-6):525-530. 10.1097/FBP.0b013e328349ab22.
64. Huber M.T., Gotthardt U., Schreiber W., Krieg J.C. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: An open clinical trial. Pharmacopsychiatry 1999, 32(2):68-72. 10.1055/s-2007-979194.
65. Hyman S.E., Malenka R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nature Reviews Neuroscience 2001, 2(10):695-703.
66. 11C]SA4503. The International Journal of Neuropsychopharmacology 2009, 12(8):1127-1131. S1461145709990204 [pii]. 10.1017/S1461145709990204.
67. Itzhak Y. Repeated methamphetamine-treatment alters brain sigma receptors. European Journal of Pharmacology 1993, 230(2):243-244.
68. Jansen K.L., Faull R.L., Dragunow M., Leslie R.A. Autoradiographic distribution of sigma receptors in human neocortex, hippocampus, basal ganglia, cerebellum, pineal and pituitary glands. Brain Research 1991, 559(1):172-177. 0006-8993(91)90303-D [pii].
69. Jovanovski D., Zakzanis K.K. Donepezil in a chronic drug user-A potential treatment?. Human Psychopharmacology 2003, 18(7):561-564. 10.1002/hup.530.
70. Jupp B., Lawrence A.J. New horizons for therapeutics in drug and alcohol abuse. Pharmacology & Therapeutics 2010, 125(1):138-168. S0163-7258(09)00212-5 [pii]. 10.1016/j.pharmthera.2009.11.002.
71. Kaushal, N. (2012). Evaluation of novel sigma receptor antagonists against methamphetamine-induced neurotoxicity: In vivo and in vitro studies. Ph.D., West Virginia University, Morgantown.
72. Kaushal N., Elliott M., Robson M.J., Iyer A.K., Rojanasakul Y., Coop A., et al. AC927, a sigma receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Molecular Pharmacology 2012, 81(3):299-308. mol.111.074120 [pii]. 10.1124/mol.111.074120.
73. Kaushal N., Matsumoto R.R. Role of sigma receptors in methamphetamine-induced neurotoxicity. Current Neuropharmacology 2011, 9(1):54-57. CN-9-54 [pii]. 10.2174/157015911795016930.
74. Kaushal, N., McCurdy, C. R., & Matsumoto, R. R. (2011). SN79 attenuates the neurotoxic effects of methamphetamine: In vivo and in vitro studies. Paper presented at the Society for Neuroscience.
75. Kaushal N., Robson M.J., Vinnakota H., Narayanan S., Avery B.A., McCurdy C.R., et al. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. The AAPS Journal 2011, 13(3):336-346. 10.1208/s12248-011-9274-9.
76. Kaushal N., Seminerio M.J., Robson M.J., McCurdy C.R., Matsumoto R.R. Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. European Neuropsychopharmacology 2013, 23:960-971. S0924-977X(12)00223-4 [pii]. 10.1016/j.euroneuro.2012.08.005.
77. Kaushal N., Seminerio M.J., Shaikh J., Medina M.A., Mesangeau C., Wilson L.L., et al. CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology 2011, 61(5-6):992-1000. S0028-3908(11)00275-9 [pii]. 10.1016/j.neuropharm.2011.06.028.
78. 1 receptors. Nuclear Medicine and Biology 2000, 27(3):255-261. S0969805100000810 [pii].
79. Kekuda R., Prasad P.D., Fei Y.J., Leibach F.H., Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochemical and Biophysical Research Communications 1996, 229(2):553-558. S0006-291X(96)91842-2 [pii]. 10.1006/bbrc.1996.1842.
80. Kelly K.A., Miller D.B., Bowyer J.F., O'Callaghan J.P. Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. Journal of Neurochemistry 2012, 122(5):995-1009. 10.1111/j.1471-4159.2012.07864.x.
81. Kinoshita M., Matsuoka Y., Suzuki T., Mirrielees J., Yang J. Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands. Brain Research 2012, 1452:1-9. S0006-8993(12)00432-5 [pii]. 10.1016/j.brainres.2012.02.070.
82. 1) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. Journal of Chemical Neuroanatomy 2000, 20(3-4):375-387. S0891-0618(00)00106-X [pii].
83. Klein M., Cooper T.B., Musacchio J.M. Effects of haloperidol and reduced haloperidol on binding to sigma sites. European Journal of Pharmacology 1994, 254(3):239-248.
84. Kourrich S., Hayashi T., Chuang J.Y., Tsai S.Y., Su T.P., Bonci A. Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Cell 2013, 152(1-2):236-247. S0092-8674(12)01491-2 [pii]. 10.1016/j.cell.2012.12.004.
85. Kourrich S., Su T.P., Fujimoto M., Bonci A. The sigma-1 receptor: Roles in neuronal plasticity and disease. Trends in Neurosciences 2012, 35(12):762-771. S0166-2236(12)00171-3 [pii]. 10.1016/j.tins.2012.09.007.
86. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Research Reviews 2009, 60(2):379-407. S0165-0173(09)00034-4 [pii]. 10.1016/j.brainresrev.2009.03.002.
87. Kuehn B.M. Nicotine, donepezil may dampen meth craving. JAMA 2006, 296(1):31. 296/1/31 [pii]. 10.1001/jama.296.1.31.
88. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. The Journal of Pharmacology and Experimental Therapeutics 1986, 238(2):739-748.
89. Lever J.R., Gustafson J.L., Xu R., Allmon R.L., Lever S.Z. Sigma-1 and sigma-2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 2006, 59(6):350-358.
90. 1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: Time course and regional distribution studies. The Journal of Pharmacology and Experimental Therapeutics 2008, 327(1):187-195. jpet.108.141051 [pii]. 10.1124/jpet.108.141051.
91. Liu Y., Whitlock B.B., Pultz J.A., Wolfe S.A. Sigma-1 receptors modulate functional activity of rat splenocytes. Journal of Neuroimmunology 1995, 59(1-2):143-154.
92. 1 agonist SA 4503: Electrophysiological, morphological and behavioural studies. The International Journal of Neuropsychopharmacology 2008, 11(4):485-495. S1461145708008547 [pii]. 10.1017/S1461145708008547.
93. Mach R.H., Wheeler K.T. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo. Central Nervous System Agents in Medicinal Chemistry 2009, 9(3):230-245.
94. Maj J., Rogoz Z., Skuza G. Some behavioral effects of 1,3-di-o-tolylguanidine, opipramol and sertraline, the sigma site ligands. Polish Journal of Pharmacology 1996, 48(4):379-395.
95. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. The Journal of Pharmacology and Experimental Therapeutics 1976, 197(3):517-532.
96. Matsumoto R.R. Targeting sigma receptors: Novel medication development for drug abuse and addiction. Expert Review of Clinical Pharmacology 2009, 2(4):351-358. 10.1586/ecp.09.18.
97. Matsumoto R.R., Bowen W.D., de Costa B.R., Houk J.C. Relationship between modulation of the cerebellorubrospinal system in the in vitro turtle brain and changes in motor behavior in rats: Effects of novel sigma ligands. Brain Research Bulletin 1999, 48(5):497-508. S0361-9230(99)00029-5 [pii].
98. Matsumoto R.R., Bowen W.D., Su T.-P. Sigma receptors: Chemistry, cell biology and clinical implications 2007, Springer, New York.
99. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., De Costa B.R. Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism. European Journal of Pharmacology 1995, 280(3):301-310.
100. Matsumoto R.R., Gilmore D.L., Pouw B., Bowen W.D., Williams W., Kausar A., et al. Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice. European Journal of Pharmacology 2004, 492(1):21-26. S0014299904002948 [pii]. 10.1016/j.ejphar.2004.03.037.
101. Matsumoto R.R., Li S.M., Katz J.L., Fantegrossi W.E., Coop A. Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug and Alcohol Dependence 2011, 118(1):40-47. S0376-8716(11)00117-7 [pii]. 10.1016/j.drugalcdep.2011.02.017.
102. Matsumoto R.R., Liu Y., Lerner M., Howard E.W., Brackett D.J. Sigma receptors: Potential medications development target for anti-cocaine agents. European Journal of Pharmacology 2003, 469(1-3):1-12. S0014299903017230 [pii].
103. Matsumoto R.R., McCracken K.A., Friedman M.J., Pouw B., De Costa B.R., Bowen W.D. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. European Journal of Pharmacology 2001, 419(2-3):163-174.
104. Matsumoto R.R., McCracken K.A., Pouw B., Miller J., Bowen W.D., Williams W., et al. N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. European Journal of Pharmacology 2001, 411(3):261-273. S0014299900009171 [pii].
105. Matsumoto R.R., McCracken K.A., Pouw B., Zhang Y., Bowen W.D. Involvement of sigma receptors in the behavioral effects of cocaine: Evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002, 42(8):1043-1055. S0028390802000564 [pii].
106. Matsumoto R.R., Potelleret F.H., Mack A., Pouw B., Zhang Y., Bowen W.D. Structure-activity comparison of YZ-069, a novel sigma ligand, and four analogs in receptor binding and behavioral studies. Pharmacology, Biochemistry and Behavior 2004, 77(4):775-781. S0091305704000322 [pii]. 10.1016/j.pbb.2004.01.014.
107. Matsumoto R.R., Shaikh J., Wilson L.L., Vedam S., Coop A. Attenuation of methamphetamine-induced effects through the antagonism of sigma (σ) receptors: Evidence from in vivo and in vitro studies. European Neuropsychopharmacology 2008, 18(12):871-881. S0924-977X(08)00177-6 [pii]. 10.1016/j.euroneuro.2008.07.006.
108. 1 protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. The Journal of Pharmacology and Experimental Therapeutics 2006, 317(2):606-614. jpet.105.097394 [pii]. 10.1124/jpet.105.097394.
109. 3H]SKF-10,047 binding to sigma 1 receptors in the mouse forebrain. Journal of Neuroscience Research 1996, 46(6):734-743.
110. Maurice T., Su T.P. The pharmacology of sigma-1 receptors. Pharmacology & Therapeutics 2009, 124(2):195-206. S0163-7258(09)00141-7 [pii]. 10.1016/j.pharmthera.2009.07.001.
111. Mavlyutov T.A., Epstein M.L., Verbny Y.I., Huerta M.S., Zaitoun I., Ziskind-Conhaim L., et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience 2013, 240:129-134. S0306-4522(13)00169-3 [pii]. 10.1016/j.neuroscience.2013.02.035.
112. 3H]SKF-10,047 binding sites (sigma sites) from rat liver membranes. The Journal of Pharmacology and Experimental Therapeutics 1991, 257(2):547-554.
113. McCracken K.A., Bowen W.D., Matsumoto R.R. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. European Journal of Pharmacology 1999, 365:35-38.
114. McLean S., Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 1988, 25(1):259-269.
115. Mei J., Pasternak G.W. Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochemical Pharmacology 2001, 62(3):349-355. S0006-2952(01)00666-9 [pii].
116. 1 receptor modulation of opioid analgesia in the mouse. The Journal of Pharmacology and Experimental Therapeutics 2002, 300(3):1070-1074.
117. 1 receptors in Parkinson's disease. Acta Neurologica Scandinavica 2005, 112(2):103-107. ANE432 [pii]. 10.1111/j.1600-0404.2005.00432.x.
118. 1 receptors in early Alzheimer's disease. Annals of Nuclear Medicine 2008, 22(3):151-156. 10.1007/s12149-007-0094-z.
119. Moebius F.F., Burrows G.G., Hanner M., Schmid E., Striessnig J., Glossmann H. Identification of a 27-kDa high affinity phenylalkylamine-binding polypeptide as the sigma 1 binding site by photoaffinity labeling and ligand-directed antibodies. Molecular Pharmacology 1993, 44(5):966-971.
120. Moller H.J., Volz H.P., Reimann I.W., Stoll K.D. Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group. Journal of Clinical Psychopharmacology 2001, 21(1):59-65.
121. Monassier L., Bousquet P. Sigma receptors: From discovery to highlights of their implications in the cardiovascular system. Fundamental & Clinical Pharmacology 2002, 16(1):1-8.
122. Monnet F.P., Debonnel G., de Montigny C. In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. The Journal of Pharmacology and Experimental Therapeutics 1992, 261(1):123-130.
123. Monnet F.P., Maurice T. The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: Molecular, physiological, and behavioral aspects. Journal of Pharmacological Sciences 2006, 100(2):93-118. JST.JSTAGE/jphs/CR0050032 [pii].
124. Mori T., Rahmadi M., Yoshizawa K., Itoh T., Shibasaki M., Suzuki T. Inhibitory effects of SA4503 on the rewarding effects of abused drugs. Addiction Biology 2012, [Epub ahead of print]. 10.1111/j.1369-1600.2012.00488.x.
125. Moriguchi S., Shinoda Y., Yamamoto Y., Sasaki Y., Miyajima K., Tagashira H., et al. Stimulation of the sigma-1 receptor by DHEA enhances synaptic efficacy and neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice. PLoS One 2013, 8(4):e60863. PONE-D-13-02750 [pii]. 10.1371/journal.pone.0060863.
126. Muller M.J., Grunder G., Wetzel H., Muller-Siecheneder F., Marx-Dannigkeit P., Benkert O. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: An open clinical trial. Psychiatry Research 1999, 89(3):275-280. S0165178199001006 [pii].
127. 3H] SKF 10047 binding with sigma-opioid receptors of the liver. Biulleten Eksperimentalnoi Biologii I Meditsiny 1988, 106(9):314-317.
128. 1 receptor-mediated effects of cocaine. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(43):18676-18681. 1008911107 [pii]. 10.1073/pnas.1008911107.
129. 2 receptor heteromers. PLoS One 2013, 8(4):e61245. PONE-D-12-34649 [pii]. 10.1371/journal.pone.0061245.
130. Neumaier J.F., Chavkin C. Calcium-dependent displacement of haloperidol-sensitive sigma receptor binding in rat hippocampal slices following tissue depolarization. Brain Research 1989, 500(1-2):215-222.
131. Nguyen E.C., McCracken K.A., Liu Y., Pouw B., Matsumoto R.R. Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: Receptor binding and behavioral studies. Neuropharmacology 2005, 49(5):638-645. S0028-3908(05)00165-6 [pii]. 10.1016/j.neuropharm.2005.04.016.
132. Nicosia N., Pacula R.L., Kilmer B., Lundberg R., Chiesa J. The economic cost of methamphetamine use in the United States, 2005 2009, RAND Drug Policy Research Center, Santa Monica. http://www.rand.org.
133. Noorbakhsh B., Seminerio M.J., Xu Y.-T., Beatty C., Mesangeau C., McCurdy C.R., et al. Synthesis and pharmacological characterization of sigma-2 preferring compounds: Implications for cocaine-induced behaviors. Society for Neuroscience Abstract 2011, #896.02.
134. Novakova M., Ela C., Barg J., Vogel Z., Hasin Y., Eilam Y. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. European Journal of Pharmacology 1995, 286(1):19-30. 0014-2999(95)00424-J [pii].
135. 2) receptors as a target for cocaine action in the rat striatum. European Journal of Pharmacology 2006, 535(1-3):98-103. S0014-2999(05)01353-1 [pii]. 10.1016/j.ejphar.2005.12.077.
136. 2 receptors in mediating cocaine-induced convulsions. Pharmacology, Biochemistry and Behavior 2000, 65(4):677-681. S0091-3057(99)00253-1 [pii].
137. Ortega-Roldan J.L., Ossa F., Schnell J.R. Characterization of the human sigma-1 receptor chaperone domain structure and binding immunoglobulin protein (BiP) interactions. The Journal of Biological Chemistry 2013, 288(29):21448-21457. M113.450379 [pii]. 10.1074/jbc.M113.450379.
138. Pal A., Chu U.B., Ramachandran S., Grawoig D., Guo L.W., Hajipour A.R., et al. Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor. The Journal of Biological Chemistry 2008, 283(28):19646-19656. M802192200 [pii]. 10.1074/jbc.M802192200.
139. Pal A., Fontanilla D., Gopalakrishnan A., Chae Y.K., Markley J.L., Ruoho A.E. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. European Journal of Pharmacology 2012, 682(1-3):12-20.
140. Palacios G., Muro A., Vela J.M., Molina-Holgado E., Guitart X., Ovalle S., et al. Immunohistochemical localization of the sigma1-receptor in oligodendrocytes in the rat central nervous system. Brain Research 2003, 961(1):92-99. S0006899302038921 [pii].
141. 1 receptor in Schwann cells of rat sciatic nerve. Brain Research 2004, 1007(1-2):65-70. S0006899304002392 [pii]. 10.1016/j.brainres.2004.02.013.
142. Pascaud X.B., Chovet M., Soulard P., Chevalier E., Roze C., Junien J.L. Effects of a new sigma ligand, JO 1784, on cysteamine ulcers and duodenal alkaline secretion in rats. Gastroenterology 1993, 104(2):427-434.
143. Paul R., Lavastre S., Floutard D., Floutard R., Canat X., Casellas P., et al. Allosteric modulation of peripheral sigma binding sites by a new selective ligand: SR 31747. Journal of Neuroimmunology 1994, 52(2):183-192.
144. Perregaard J., Moltzen E.K., Meier E., Sanchez C. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. Journal of Medicinal Chemistry 1995, 38(11):1998-2008.
145. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nature Reviews Neurology 2010, 6(4):193-201. nrneurol.2010.17 [pii]. 10.1038/nrneurol.2010.17.
146. Prasad P.D., Li H.W., Fei Y.J., Ganapathy M.E., Fujita T., Plumley L.H., et al. Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. Journal of Neurochemistry 1998, 70(2):443-451.
147. Raivich G., Bohatschek M., Kloss C.U., Werner A., Jones L.L., Kreutzberg G.W. Neuroglial activation repertoire in the injured brain: Graded response, molecular mechanisms and cues to physiological function. Brain Research. Brain Research Reviews 1999, 30(1):77-105. S0165017399000077 [pii].
148. 1 receptor interacts with N-alkyl amines and endogenous sphingolipids. European Journal of Pharmacology 2009, 609(1-3):19-26.
149. Ramachandran S., Lu H., Prabhu U., Ruoho A.E. Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli. Protein Expression and Purification 2007, 51(2):283-292. S1046-5928(06)00231-2 [pii]. 10.1016/j.pep.2006.07.019.
150. Rao T.S., Cler J.A., Mick S.J., Dilworth V.M., Contreras P.C., Iyengar S., et al. Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo. Neuropharmacology 1990, 29(12):1191-1197.
151. Robson, M. J. (2013). The involvement of sigma receptor modulation in the antidepressant effects of ketamine and the neurotoxic actions of methamphetamine. Ph.D., West Virginia University, Morgantown.
152. Robson M.J., McCurdy C.R., Matsumoto R.R. Methamphetamine elicits PERK-mediated endoplasmic reticulum transcriptional responses in NG108-15 cells. Society for Neuroscience 2012, Abstract, #360.12.
153. Robson M.J., Seminerio M.J., McCurdy C.R., Coop A., Matsumoto R.R. σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacological Reports 2013, 65(2):343-349.
154. Robson M.J., Turner R.C., Naser Z.J., McCurdy C.R., Huber J.D., Matsumoto R.R. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Experimental Neurology 2013, 247C:134-142. S0014-4886(13)00137-4 [pii]. 10.1016/j.expneurol.2013.04.009.
155. Rockhold R.W. Glutamatergic involvement in psychomotor stimulant action. Progress in Drug Research 1998, 50:155-192.
156. Rodvelt K.R., Oelrichs C.E., Blount L.R., Fan K.H., Lever S.Z., Lever J.R., et al. The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine. Drug and Alcohol Dependence 2011, 116(1-3):203-210. S0376-8716(11)00040-8 [pii]. 10.1016/j.drugalcdep.2010.12.018.
157. Romieu P., Martin-Fardon R., Bowen W.D., Maurice T. Sigma1 receptor-related neuroactive steroids modulate cocaine-induced reward. The Journal of Neuroscience 2003, 23(9):3572-3576. 23/9/3572 [pii].
158. 1 receptor in the cocaine-induced conditioned place preference. Neuroreport 2000, 11(13):2885-2888.
159. 1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacology 2004, 175(2):154-162. 10.1007/s00213-004-1814-x.
160. 1 receptor in cocaine-induced conditioned place preference: Possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002, 26(4):444-455. S0893133X01003918 [pii]. 10.1016/S0893-133X(01)00391-8.
161. Roze C., Bruley Des Varannes S., Shi G., Geneve J., Galmiche J.P. Inhibition of prostaglandin-induced intestinal secretion by igmesine in healthy volunteers. Gastroenterology 1998, 115(3):591-596.
162. Ruscher K., Shamloo M., Rickhag M., Ladunga I., Soriano L., Gisselsson L., et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 2011, 134(Pt. 3):732-746. awq367 [pii]. 10.1093/brain/awq367.
163. Sabino V., Cottone P., Blasio A., Iyer M.R., Steardo L., Rice K.C., et al. Activation of sigma-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology 2011, 36(6):1207-1218. npp20115 [pii]. 10.1038/npp.2011.5.
164. Saijo K., Glass C.K. Microglial cell origin and phenotypes in health and disease. Nature Reviews Immunology 2011, 11(11):775-787. nri3086 [pii]. 10.1038/nri3086.
165. 2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behavioural Pharmacology 2000, 11(2):117-124.
166. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. The American Journal of Psychiatry 2001, 158(8):1206-1214.
167. Sekine Y., Minabe Y., Ouchi Y., Takei N., Iyo M., Nakamura K., et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. The American Journal of Psychiatry 2003, 160(9):1699-1701.
168. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brains of human abusers. The Journal of Neuroscience 2008, 28(22):5756-5761. 28/22/5756 [pii]. 10.1523/JNEUROSCI.1179-08.2008.
169. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Archives of General Psychiatry 2006, 63(1):90-100. 63/1/90 [pii]. 10.1001/archpsyc.63.1.90.
170. Seminerio M.J., Hansen R., Kaushal N., Zhang H.T., McCurdy C.R., Matsumoto R.R. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. The International Journal of Neuropsychopharmacology 2013, 16(5):1033-1044. S1461145712000831 [pii]. 10.1017/S1461145712000831.
171. Seminerio M.J., Kaushal N., Shaikh J., Huber J.D., Coop A., Matsumoto R.R. Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacology, Biochemistry and Behavior 2011, 98(1):12-20. S0091-3057(10)00361-8 [pii]. 10.1016/j.pbb.2010.11.023.
172. Seminerio M.J., Robson M.J., Abdelazeem A.H., Mesangeau C., Jamalapuram S., Avery B.A., et al. Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. The AAPS Journal 2012, 14(1):43-51. 10.1208/s12248-011-9311-8.
173. Seminerio M.J., Robson M.J., McCurdy C.R., Matsumoto R.R. Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1β mRNA expression in the hypothalamus. European Journal of Pharmacology 2012, 691(1-3):103-109. S0014-2999(12)00623-1 [pii]. 10.1016/j.ejphar.2012.07.029.
174. Sha S., Qu W.J., Li L., Lu Z.H., Chen L., Yu W.F. Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors. CNS Neuroscience & Therapeutics 2013, 19:705-713. 10.1111/cns.12129.
175. Sharkey J., Glen K.A., Wolfe S., Kuhar M.J. Cocaine binding at sigma receptors. European Journal of Pharmacology 1988, 149(1-2):171-174. 0014-2999(88)90058-1 [pii].
176. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Kao U.H., Wang P.C., Bholat M.A., et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal of Addictive Diseases 2008, 27(1):13-23. 10.1300/J069v27n01_02.
177. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Steward T., Wang J., Swanson A.N., et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and Alcohol Dependence 2008, 96(3):222-232. S0376-8716(08)00104-X [pii]. 10.1016/j.drugalcdep.2008.03.010.
178. Shoptaw S., Huber A., Peck J., Yang X., Liu J., Jeff D., et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug and Alcohol Dependence 2006, 85(1):12-18. S0376-8716(06)00075-5 [pii]. 10.1016/j.drugalcdep.2006.03.005.
179. Shoptaw S., Majewska M.D., Wilkins J., Twitchell G., Yang X., Ling W. Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. Experimental and Clinical Psychopharmacology 2004, 12(2):126-135. 2004-13592-005 [pii]. 10.1037/1064-1297.12.2.126.
180. Slifer B.L., Balster R.L. Reinforcing properties of stereoisomers of the putative sigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 1983, 225(3):522-528.
181. Spruce B.A., Campbell L.A., McTavish N., Cooper M.A., Appleyard M.V., O'Neill M., et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Research 2004, 64(14):4875-4886.
182. 1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls. Psychopharmacology 2004, 175(1):68-75. 10.1007/s00213-004-1779-9.
183. Stone J.M., Arstad E., Erlandsson K., Waterhouse R.N., Ell P.J., Pilowsky L.S. [123I]TPCNE-a novel SPET tracer for the sigma-1 receptor: First human studies and in vivo haloperidol challenge. Synapse 2006, 60(2):109-117. 10.1002/syn.20281.
184. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. The Journal of Pharmacology and Experimental Therapeutics 1982, 223(2):284-290.
185. Su T.P., Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Current Medicinal Chemistry 2003, 10(20):2073-2080.
186. Su T.P., Hayashi T., Maurice T., Buch S., Ruoho A.E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends in Pharmacological Sciences 2010, 31(12):557-566. S0165-6147(10)00153-7 [pii]. 10.1016/j.tips.2010.08.007.
187. Su T.P., London E.D., Jaffe J.H. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988, 240(4849):219-221.
188. Su T.P., Weissman A.D., Yeh S.Y. Endogenous ligands for sigma opioid receptors in the brain ("sigmaphin"): Evidence from binding assays. Life Sciences 1986, 38(24):2199-2210.
189. Substance Abuse and Mental Health Services Administration. (2008). Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Visits.
190. Substance Abuse and Mental Health Services Administration. (2009). 2008 National Survey on Drug Use and Health.
191. 1 receptors in methamphetamine-induced behavioral sensitization in rats. Neuroscience Letters 2000, 289(1):21-24. S0304-3940(00)01258-1 [pii].
192. Takebayashi M., Hayashi T., Su T.P. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: Implications for antidepressants. The Journal of Pharmacology and Experimental Therapeutics 2002, 303(3):1227-1237. 10.1124/jpet.102.041970.
193. Tam S.W. Naloxone-inaccessible sigma receptor in rat central nervous system. Proceedings of the National Academy of Sciences of the United States of America 1983, 80(21):6703-6707.
194. 3H]haloperidol binding in guinea pig brain membranes. Proceedings of the National Academy of Sciences of the United States of America 1984, 81(17):5618-5621.
195. Terleckyj I., Sonsalla P.K. The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. The Journal of Pharmacology and Experimental Therapeutics 1994, 269(1):44-50.
196. Theodorou V., Chovet M., Eutamene H., Fargeau H., Dassaud M., Toulouse M., et al. Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: Mechanisms of action. Gut 2002, 51(4):522-528.
197. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neuroscience Letters 2004, 367(3):349-354. S0304-3940(04)00767-0 [pii]. 10.1016/j.neulet.2004.06.065.
198. 11C]SA4503. Central Nervous System Agents in Medicinal Chemistry 2009, 9(3):190-196.
199. 1 receptors in the brain: Contributions of emopamil binding protein. Nuclear Medicine and Biology 2012, 39(7):1049-1052. S0969-8051(12)00053-4 [pii]. 10.1016/j.nucmedbio.2012.03.002.
200. Ujike H., Kanazaki A., Okumura K., Akiyama K., Otsuki S. Sigma (σ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sciences 1992, 50(16):L129-L134.
201. Ujike H., Kuroda S., Otsuki S. Sigma receptor antagonists block the development of sensitization to cocaine. European Journal of Pharmacology 1996, 296(2):123-128.
202. United Nations Office on Drugs and Crime. (2010). World Drug Report 2010.
203. van Waarde A., Rybczynska A.A., Ramakrishnan N., Ishiwata K., Elsinga P.H., Dierckx R.A. Sigma receptors in oncology: Therapeutic and diagnostic applications of sigma ligands. Current Pharmaceutical Design 2010, 16(31):3519-3537. BSP/CPD/E-Pub/000240 [pii].
204. Vilner B.J., Bowen W.D. Modulation of cellular calcium by sigma-2 receptors: Release from intracellular stores in human SK-N-SH neuroblastoma cells. The Journal of Pharmacology and Experimental Therapeutics 2000, 292(3):900-911.
205. Vilner B.J., John C.S., Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Research 1995, 55(2):408-413.
206. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. The Journal of Neuroscience 2001, 21(23):9414-9418. 21/23/9414 [pii].
207. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. The American Journal of Psychiatry 2001, 158(3):377-382.
208. Volz H.P., Stoll K.D. Clinical trials with sigma ligands. Pharmacopsychiatry 2004, 37(Suppl. 3):S214-S220. 10.1055/s-2004-832680.
209. Vu T.H., Weissman A.D., London E.D. Pharmacological characteristics and distributions of sigma- and phencyclidine receptors in the animal kingdom. Journal of Neurochemistry 1990, 54(2):598-604.
210. 2 receptors in motor function. European Journal of Pharmacology 1993, 231(1):61-68.
211. 1 receptor in human breast cancer. Breast Cancer Research and Treatment 2004, 87(3):205-214.
212. 18F]1-(2-fluoroethyl)-4-[(4-cyanophenoxy)methyl]piperidine as a potential radiotracer for PET assessment of CNS sigma-1 receptors. Nuclear Medicine and Biology 2006, 33(2):211-215. S0969-8051(05)00270-2 [pii]. 10.1016/j.nucmedbio.2005.10.007.
213. 3H]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(22):8784-8788.
214. Wilbert-Lampen U., Seliger C., Zilker T., Arendt R.M. Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: Reversal by coincubation with sigma-receptor antagonists. Circulation 1998, 98(5):385-390.
215. Winhusen T.M., Somoza E.C., Harrer J.M., Mezinskis J.P., Montgomery M.A., Goldsmith R.J., et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005, 100(Suppl. 1):68-77. ADD992 [pii]. 10.1111/j.1360-0443.2005.00992.x.
216. Witkin J.M., Terry P., Menkel M., Hickey P., Pontecorvo M., Ferkany J., et al. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. The Journal of Pharmacology and Experimental Therapeutics 1993, 266(2):473-482.
217. Wolfe S.A., Kulsakdinun C., Battaglia G., Jaffe J.H., De Souza E.B. Initial identification and characterization of sigma receptors on human peripheral blood leukocytes. The Journal of Pharmacology and Experimental Therapeutics 1988, 247(3):1114-1119.
218. Woods S.P., Rippeth J.D., Conover E., Gongvatana A., Gonzalez R., Carey C.L., et al. Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology 2005, 19(1):35-43. 2005-00128-005 [pii]. 10.1037/0894-4105.19.1.35.
219. Wu Z., Bowen W.D. Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: Constitutive enhancement of calcium signaling in MCF-7 tumor cells. The Journal of Biological Chemistry 2008, 283(42):28198-28215. M802099200 [pii]. 10.1074/jbc.M802099200.
220. Xu Y.T., Kaushal N., Shaikh J., Wilson L.L., Mesangeau C., McCurdy C.R., et al. A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. The Journal of Pharmacology and Experimental Therapeutics 2010, 333(2):491-500. jpet.109.161398 [pii]. 10.1124/jpet.109.161398.
221. Xu Y.T., Robson M.J., Szeszel-Fedorowicz W., Patel D., Rooney R., McCurdy C.R., et al. CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. Pharmacology, Biochemistry and Behavior 2012, 101(1):174-180. S0091-3057(11)00437-0 [pii]. 10.1016/j.pbb.2011.12.016.
222. Xu J., Zeng C., Chu W., Pan F., Rothfuss J.M., Zhang F., et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nature Communications 2011, 2:380. ncomms1386 [pii]. 10.1038/ncomms1386.
223. Yamamoto H., Miura R., Yamamoto T., Shinohara K., Watanabe M., Okuyama S., et al. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Letters 1999, 445(1):19-22. S0014-5793(99)00084-8 [pii].
224. Yang S., Alkayed N.J., Hurn P.D., Kirsch J.R. Cyclic adenosine monophosphate response element-binding protein phosphorylation and neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP). Anesthesia and Analgesia 2009, 108(3):964-970. 108/3/964 [pii]. 10.1213/ane.0b013e318192442c.
225. Yao H., Duan M., Buch S. Cocaine-mediated induction of platelet-derived growth factor: Implication for increased vascular permeability. Blood 2011, 117(8):2538-2547. blood-2010-10-313593 [pii]. 10.1182/blood-2010-10-313593.
226. 1 receptor to initiate induction of activated leukocyte cell adhesion molecule: Implication for increased monocyte adhesion and migration in the CNS. The Journal of Neuroscience 2011, 31(16):5942-5955. 31/16/5942 [pii]. 10.1523/JNEUROSCI.5618-10.2011.
227. Yao H., Yang Y., Kim K.J., Bethel-Brown C., Gong N., Funa K., et al. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: Implication for increased monocyte transmigration. Blood 2010, 115(23):4951-4962. blood-2010-01-266221 [pii]. 10.1182/blood-2010-01-266221.
228. Zamanillo D., Romero L., Merlos M., Vela J.M. Sigma1 receptor: A new therapeutic target for pain. European Journal of Pharmacology 2013, 716:78-93. S0014-2999(13)00167-2 [pii]. 10.1016/j.ejphar.2013.01.068.
229. Zeng C., Vangveravong S., Xu J., Chang K.C., Hotchkiss R.S., Wheeler K.T., et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Research 2007, 67(14):6708-6716. 67/14/6708 [pii]. 10.1158/0008-5472.CAN-06-3803.
230. Zhang H., Cuevas J. Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. Journal of Neurophysiology 2002, 87(6):2867-2879.
231. Zhang H., Cuevas J. Sigma receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):1387-1396. jpet.105.084152 [pii]. 10.1124/jpet.105.084152.